AstraZeneca
AZN
1,054 hedge funds and large institutions have $35B invested in AstraZeneca in 2023 Q1 according to their latest regulatory filings, with 87 funds opening new positions, 403 increasing their positions, 348 reducing their positions, and 69 closing their positions.
26% more first-time investments, than exits
New positions opened: 87 | Existing positions closed: 69
16% more repeat investments, than reductions
Existing positions increased: 403 | Existing positions reduced: 348
5% more call options, than puts
Call options by funds: $487M | Put options by funds: $466M
3% more capital invested
Capital invested by funds: $34.1B → $35B (+$913M)
0.01% more ownership
Funds ownership: 16.38% → 16.39% (+0.01%)
1% less funds holding
Funds holding: 1,061 → 1,054 (-7)
32% less funds holding in top 10
Funds holding in top 10: 19 → 13 (-6)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
+$733M |
| 2 |
GQG Partners
Ft. Lauderdale,
Florida
|
+$293M |
| 3 |
Envestnet Asset Management
Chicago,
Illinois
|
+$274M |
| 4 |
Morgan Stanley
New York
|
+$184M |
| 5 |
Goldman Sachs
New York
|
+$103M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$657M |
| 2 |
BlackRock
New York
|
-$205M |
| 3 |
Capital International Investors
Los Angeles,
California
|
-$180M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$131M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$126M |
AZN Hedge Fund Activity: Q1 2023 in Review
1,054 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in AstraZeneca (AZN) for Q1 2023, worth a combined $35B — up 2.7% from $34.1B a quarter earlier.
Buyers outnumbered sellers: 87 funds opened new AZN positions and 69 closed out — a net gain of 18 holders — while 403 added to existing stakes and 348 trimmed.
The largest buyer was Jennison Associates, adding an estimated $733M. The largest seller was T. Rowe Price Associates, cutting an estimated $657M.
- 1,054 institutional investors held AstraZeneca (AZN) as of Q1 2023, down from 1,061 in Q4 2022.
- Funds reported $35B of AstraZeneca stock for Q1 2023, up 2.7% quarter-over-quarter.
- 87 funds opened new AstraZeneca positions in Q1 2023 and 69 closed out, a net change of +18 holders.
- The largest AstraZeneca buyer in Q1 2023 was Jennison Associates, an estimated $733M added.
- The largest AstraZeneca seller in Q1 2023 was T. Rowe Price Associates, an estimated $657M sold.
Based on aggregated 13F filings for Q1 2023.